Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “interleukin-”

120 pharma patents match "interleukin-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 120
Index total 30,257
Page 2 / 5

Quick answer

This filtered view shows 120 pharmaceutical patents matching "interleukin-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

120 results for “interleukin-” · 30,257 patents in full index Clear search

  1. US 11464830

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted
  2. US 11421036

    Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  3. US 11352403

    Activatable interleukin-2 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  4. US 11352402

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  5. US 11318164

    Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy

    Nektar Therapeutics · Granted May 3, 2022 · Expires Apr 28, 2042

    granted
  6. US 11118186

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  7. US 11098127

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 24, 2021 · Expires Aug 19, 2041

    granted
  8. US 11091525

    Method of refolding an interleukin-2 (IL-2) protein

    Nektar Therapeutics · Granted Aug 17, 2021 · Expires Aug 12, 2041

    granted
  9. US 11084856

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted
  10. US 11059896

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  11. US 11041000

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  12. US 11026997

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  13. US 11013787

    Sustained release formulation of interleukin-10 for wound treatment and related methods

    THE REGENTS OF THE UNIVERSITY OF COLORADO FOR AND ON BEHALF OF THE UNIVERSITY OF COLORADO DENVER · Granted May 25, 2021 · Expires May 20, 2041

    granted
  14. US 11008314

    Compounds and methods for modulating interleukin-2-inducible t-cell kinase

    Corvus Pharmaceuticals, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted
  15. US 11007265

    Vaccines having an antigen and interleukin-21 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted
  16. US 10941183

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  17. US 10933130

    Vaccines with interleukin-33 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  18. US 10851158

    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  19. US 10787490

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted
  20. US 10781242

    Interleukin-2 fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted
  21. US 10738112

    Anti-human interleukin-17A monoclonal antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  22. US 10696724

    Activatable interleukin-2 polypeptides

    Werewolf Therapeutics, Inc. · Granted Jun 30, 2020 · Expires Jun 25, 2040

    granted
  23. US 10611845

    Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  24. US 10435473

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted